Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase

Kundu,Juthika; Choi,Bu  Young; Jeong,Chul-Ho; Kundu,Joydeb  Kumar; Chun,Kyung-Soo

doi:10.3892/or.2014.3223

Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase

Authors:
- Juthika Kundu
- Bu Young Choi
- Chul-Ho Jeong
- Joydeb Kumar Kundu
- Kyung-Soo Chun
View Affiliations

Affiliations: College of Pharmacy, Keimyung University, Dalseo-Gu, Daegu 704-701, Republic of Korea, Department of Pharmaceutical Science and Engineering, Seowon University, Cheongju, Chungbuk 361-7472, Republic of Korea
Published online on: May 29, 2014 https://doi.org/10.3892/or.2014.3223
Pages: 821-828

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Thymoquinone (TQ), a compound isolated from black seed oil (Nigella sativa), has been reported to possess anti-inflammatory and anticancer activities. However, the molecular mechanisms underlying the anticancer effects of TQ remain poorly understood. In the present study, we found that TQ significantly reduced the viability of human colon cancer HCT116 cells in a concentration- and time-dependent manner. Treatment of cells with TQ induced apoptosis, which was associated with the upregulation of Bax and inhibition of Bcl-2 and Bcl-xl expression. TQ also activated caspase-9,-7, and -3, and induced the cleavage of poly-(ADP-ribose) polymerase (PARP). Pretreatment with a pan-caspase inhibitor, z-VAD-fmk, abrogated TQ-induced apoptosis by blocking the cleavage of caspase-3 and PARP. Treatment of cells with TQ also diminished the constitutive phosphorylation, nuclear localization and the reporter gene activity of signal transducer and activator of transcription-3 (STAT3). TQ attenuated the expression of STAT3 target gene products, such as survivin, c-Myc, and cyclin-D1, -D2, and enhanced the expression of cell cycle inhibitory proteins p27 and p21. Treatment with TQ attenuated the phosphorylation of upstream kinases, such as Janus-activated kinase-2 (JAK2), Src kinase and epidermal growth factor receptor (EGFR) tyrosine kinase. Pharmacological inhibition of JAK2 and Src blunted tyrosine phosphorylation of EGFR and STAT3, while treatment with an EGFR tyrosine kinase inhibitor gefitinib inhibited phosphorylation of STAT3 without affecting that of JAK2 and Src in HCT116 cells. Collectively, our study revealed that TQ induced apoptosis in HCT116 cells by blocking STAT3 signaling via inhibition of JAK2- and Src-mediated phosphorylation of EGFR tyrosine kinase.

View Figures

View References

1	Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
3	Merika E, Saif MW, Katz A, Syrigos K and Morse M: Review. Colon cancer vaccines: an update. In Vivo. 24:607–628. 2010.PubMed/NCBI
4	Chung MY, Lim TG and Lee KW: Molecular mechanisms of chemopreventive phytochemicals against gastroenterological cancer development. World J Gastroenterol. 19:984–993. 2013. View Article : Google Scholar : PubMed/NCBI
5	Banerjee S, Padhye S, Azmi A, et al: Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer. 62:938–946. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kundu J, Kim DH, Kundu JK and Chun KS: Thymoquinone induces heme oxygenase-1 expression in HaCaT cells via Nrf2/ARE activation: Akt and AMPKα as upstream targets. Food Chem Toxicol. 65:18–26. 2014.PubMed/NCBI
7	Kundu JK, Liu L, Shin JW and Surh YJ: Thymoquinone inhibits phorbol ester-induced activation of NF-κB and expression of COX-2, and induces expression of cytoprotective enzymes in mouse skin in vivo. Biochem Biophys Res Commun. 438:721–727. 2013.PubMed/NCBI
8	Lei X, Lv X, Liu M, et al: Thymoquinone inhibits growth and augments 5-fluorouracil-induced apoptosis in gastric cancer cells both in vitro and in vivo. Biochem Biophys Res Commun. 417:864–868. 2012. View Article : Google Scholar : PubMed/NCBI
9	Yi T, Cho SG, Yi Z, et al: Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. Mol Cancer Ther. 7:1789–1796. 2008. View Article : Google Scholar : PubMed/NCBI
10	Gali-Muhtasib H, Diab-Assaf M, Boltze C, et al: Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol. 25:857–866. 2004.PubMed/NCBI
11	Gali-Muhtasib H, Ocker M, Kuester D, et al: Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. J Cell Mol Med. 12:330–342. 2008. View Article : Google Scholar : PubMed/NCBI
12	Jafri SH, Glass J, Shi R, Zhang S, Prince M and Kleiner-Hancock H: Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo. J Exp Clin Cancer Res. 29:872010. View Article : Google Scholar : PubMed/NCBI
13	Kaseb AO, Chinnakannu K, Chen D, et al: Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 67:7782–7788. 2007. View Article : Google Scholar : PubMed/NCBI
14	Jrah-Harzallah H, Ben-Hadj-Khalifa S, Almawi WY, Maaloul A, Houas Z and Mahjoub T: Effect of thymoquinone on 1,2-dimethyl-hydrazine-induced oxidative stress during initiation and promotion of colon carcinogenesis. Eur J Cancer. 49:1127–1135. 2013. View Article : Google Scholar : PubMed/NCBI
15	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
16	Burz C, Berindan-Neagoe I, Balacescu O and Irimie A: Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta Oncol. 48:811–821. 2009. View Article : Google Scholar : PubMed/NCBI
17	Martin SJ and Green DR: Protease activation during apoptosis: death by a thousand cuts? Cell. 82:349–352. 1995. View Article : Google Scholar : PubMed/NCBI
18	Ihle JN: The Stat family in cytokine signaling. Curr Opin Cell Biol. 13:211–217. 2001. View Article : Google Scholar : PubMed/NCBI
19	Slattery ML, Lundgreen A, Kadlubar SA, Bondurant KL and Wolff RK: JAK/STAT/SOCS-signaling pathway and colon and rectal cancer. Mol Carcinog. 52:155–166. 2013. View Article : Google Scholar : PubMed/NCBI
20	Laird AD, Li G, Moss KG, et al: Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Mol Cancer Ther. 2:461–469. 2003.
21	Berclaz G, Altermatt HJ, Rohrbach V, Siragusa A, Dreher E and Smith PD: EGFR dependent expression of STAT3 (but not STAT1) in breast cancer. Int J Oncol. 19:1155–1160. 2001.PubMed/NCBI
22	Chan KS, Carbajal S, Kiguchi K, Clifford J, Sano S and DiGiovanni J: Epidermal growth factor receptor-mediated activation of Stat3 during multistage skin carcinogenesis. Cancer Res. 64:2382–2389. 2004. View Article : Google Scholar : PubMed/NCBI
23	Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al: Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? Ann NY Acad Sci. 1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
24	Johnston PA and Grandis JR: STAT3 signaling: anticancer strategies and challenges. Mol Interv. 11:18–26. 2011. View Article : Google Scholar : PubMed/NCBI
25	Masuda M, Suzui M, Yasumatu R, et al: Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 62:3351–3355. 2002.PubMed/NCBI
26	Dowlati A, Nethery D and Kern JA: Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther. 3:459–463. 2004.PubMed/NCBI
27	Kong L, Deng Z, Shen H and Zhang Y: Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173. Mol Cell Biochem. 348:11–19. 2011. View Article : Google Scholar : PubMed/NCBI
28	Kopetz S: Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. Gastrointest Cancer Res. 1:S37–S41. 2007.PubMed/NCBI
29	Mann JR, Backlund MG and DuBois RN: Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat Clin Pract Oncol. 2:202–210. 2005. View Article : Google Scholar : PubMed/NCBI
30	Woo CC, Kumar AP, Sethi G and Tan KH: Thymoquinone: potential cure for inflammatory disorders and cancer. Biochem Pharmacol. 83:443–451. 2012. View Article : Google Scholar : PubMed/NCBI
31	El-Najjar N, Chatila M, Moukadem H, et al: Reactive oxygen species mediate thymoquinone-induced apoptosis and activate ERK and JNK signaling. Apoptosis. 15:183–195. 2010. View Article : Google Scholar : PubMed/NCBI
32	Gali-Muhtasib H, Kuester D, Mawrin C, et al: Thymoquinone triggers inactivation of the stress response pathway sensor CHEK1 and contributes to apoptosis in colorectal cancer cells. Cancer Res. 68:5609–5618. 2008. View Article : Google Scholar : PubMed/NCBI
33	Koka PS, Mondal D, Schultz M, Abdel-Mageed AB and Agrawal KC: Studies on molecular mechanisms of growth inhibitory effects of thymoquinone against prostate cancer cells: role of reactive oxygen species. Exp Biol Med. 235:751–760. 2010. View Article : Google Scholar : PubMed/NCBI
34	Hussain AR, Uddin S, Ahmed M, Al-Dayel F, Bavi PP and Al-Kuraya KS: Phosphorylated IκBα predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS release. PLoS One. 8:e605402013.
35	Valassiadou KE, Stefanaki K, Tzardi M, et al: Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas. Anticancer Res. 17:2571–2576. 1997.PubMed/NCBI
36	Bonnotte B, Favre N, Moutet M, et al: Bcl-2-mediated inhibition of apoptosis prevents immunogenicity and restores tumorigenicity of spontaneously regressive tumors. J Immunol. 161:1433–1438. 1998.PubMed/NCBI
37	Dobi E, Monnien F, Kim S, et al: Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 12:28–36. 2013. View Article : Google Scholar : PubMed/NCBI
38	Corvinus FM, Orth C, Moriggl R, et al: Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 7:545–555. 2005. View Article : Google Scholar : PubMed/NCBI
39	Lin Q, Lai R, Chirieac LR, et al: Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am J Pathol. 167:969–980. 2005. View Article : Google Scholar : PubMed/NCBI
40	Badr G, Mohany M and Abu-Tarboush F: Thymoquinone decreases F-actin polymerization and the proliferation of human multiple myeloma cells by suppressing STAT3 phosphorylation and Bcl2/Bcl-XL expression. Lipids Health Dis. 10:236–243. 2011. View Article : Google Scholar : PubMed/NCBI
41	Li F, Rajendran P and Sethi G: Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway. Br J Pharmacol. 161:541–554. 2010. View Article : Google Scholar
42	Zhang X, Liu P, Zhang B, Mao H, Shen L and Ma Y: Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo. Int J Mol Med. 32:623–628. 2013.PubMed/NCBI
43	Kanda N, Seno H, Konda Y, et al: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene. 23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI
44	Asanuma K, Tsuji N, Endoh T, Yagihashi A and Watanabe N: Survivin enhances Fas ligand expression via up-regulation of specificity protein 1-mediated gene transcription in colon cancer cells. J Immunol. 172:3922–3929. 2004. View Article : Google Scholar : PubMed/NCBI
45	Lin L, Liu A, Peng Z, et al: STAT3 is necessary for proliferation and survival in colon cancer-initiating cells. Cancer Res. 71:7226–7237. 2011. View Article : Google Scholar : PubMed/NCBI
46	Forgue-Lafitte ME, Coudray AM, Breant B and Mester J: Proliferation of the human colon carcinoma cell line HT29: autocrine growth and deregulated expression of the c-myc oncogene. Cancer Res. 49:6566–6571. 1989.PubMed/NCBI
47	Abukhdeir AM and Park BH: P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 10:e192008. View Article : Google Scholar : PubMed/NCBI
48	Nourazarian AR, Najar AG, Farajnia S, Khosroushahi AY, Pashaei-Asl R and Omidi Y: Combined EGFR and c-Src antisense oligodeoxynucleotides encapsulated with PAMAM Denderimers inhibit HT-29 colon cancer cell proliferation. Asian Pac J Cancer Prev. 13:4751–4756. 2012. View Article : Google Scholar
49	Boehm AL, Sen M, Seethala R, et al: Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol. 73:1632–1642. 2008. View Article : Google Scholar : PubMed/NCBI